Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Waldschmidt, D. [1 ]
El-Khoueir, A. B. [2 ]
Kim, R. D. [3 ]
Harris, W. P. [4 ]
Sung, M. W. [5 ]
Iqbal, S. [2 ]
Zhang, A. [6 ]
Nakajima, K. [6 ]
Galle, P. R. [7 ]
机构：
[1] Univ Klin Koln, Klin Gastroenterol & Hepatol, Cologne, Germany
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[5] Tisch Canc Inst Mt Sinai, New York, NY USA
[6] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[7] Univ Med Ctr Mainz, Mainz, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
153
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [21] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [22] A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED UROTHELIAL CANCER
    Gupta, Shilpa
    O'Donnell, Peter
    Plimack, Elizabeth R.
    Berger, Ranaan
    Montgomery, Bruce
    Heath, Karl
    Dolled-Filhart, Marisa
    Pathiraja, Kumudu
    Gause, Christine K.
    Cheng, Jonathan
    Perini, Rodolfo
    Bellmunt, Joaquim
    JOURNAL OF UROLOGY, 2015, 193 (04): : E861 - E862
  • [23] Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom
    Trojan, Joerg
    Cebon, Jonathan
    Liem, Andre K.
    Lipton, Lara
    Gupta, Charu
    Wu, Benjamin
    Bass, Michael
    Hollywood, Ellen
    Ma, Jennifer
    Bradley, Margaret
    Litten, Jason
    Saltz, Leonard B.
    ONCOLOGIST, 2017, 22 (07): : 780 - +
  • [24] A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari D.
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kraljevic, Silvija
    Ishikawa, Kohei
    Siegel, Abby B.
    Kumada, Hiromitsu
    Young, Louise
    Okusaka, Takuji
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 105 - 105
  • [25] A Phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
    Ikeda, M.
    Sung, M. W.
    Kudo, M.
    Kobayashi, M.
    Baron, A. D.
    Finn, R. S.
    Kaneko, S.
    Zhu, A. X.
    Kubota, T.
    Kraljevic, S.
    Ishikawa, K.
    Siegel, A. B.
    Kumada, H.
    Okusaka, T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 37 - 37
  • [26] The DASH Study: A phase 1b study of dalantercept plus sorafenib in advanced hepatocellular carcinoma
    Abou-Alfa, Ghassan K.
    Miksad, Rebecca A.
    Gutierrez, Martin
    Tejani, Mohamedtaki Abdulaziz
    Sharma, Manish
    Sun, Weijing
    Henderson, Charles A.
    Baron, Ari David
    Olowokure, Olugbenga Olanrele
    Pearsall, R. Scott
    Wilson, Dawn
    Korth, Chris
    Sherman, Matthew L.
    Pandya, Shuchi Sumant
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [27] Phase 1b study of first-line Ramucirumab plus Platinum plus Fluoropyrimidine in Japanese Patients with advanced gastric cancer
    Kadowaki, Shigenori
    Shitara, Kohei
    Sakai, Daisuke
    Nishina, Tomohiro
    Yoshikawa, Reigetsu
    Piao, Yongzhe
    Ozeki, Akichika
    Inoue, Koichi
    Muro, Kei
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study
    Hao, Chunyi
    Du, Chengyou
    Peng, Baogang
    Zhang, Wu
    Shan, Yunfeng
    Lv, Ang
    Wu, Jianhui
    Shang, Changzhen
    Luo, Xuan
    Wei, Jinxing
    Xiao, Heng
    Qiu, Jianguo
    Hua, Yunpeng
    Shen, Shunli
    Wang, Ting
    Dai, Shengjie
    Chen, Xiang
    Yan, Shican
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Karwal, Mark
    Verslype, Chris
    Van Vlierberghe, Hans
    Kardosh, Adel
    Zagonel, Vittorina
    Stal, Per
    Sarker, Debashis
    Palmer, Daniel H.
    Vogel, Arndt
    Edeline, Julien
    Cattan, Stephane
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Ogasawara, Sadahisa
    Siegel, Abby B.
    Chisamore, Michael Jon
    Wang, Anran
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC)
    Kudo, Masatoshi
    Finn, Richard S.
    Edeline, Julien
    Cattan, Stephane
    Ogasawara, Sadahisa
    Palmer, Daniel H.
    Verslype, Chris
    Zagonel, Vittorina
    Fartoux, Laetitia
    Vogel, Arndt
    Sarker, Debashis
    Verset, Gontran
    Chan, Stephen Lam
    Knox, Jennifer J.
    Daniele, Bruno
    Gurary, Ellen B.
    Siegel, Abby B.
    Jain, Lokesh
    Cheng, Ann-Lii
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345